Effects of Amantadine on Postoperative Cognitive Dysfunction

Sponsor
Zhiyi Zuo (Other)
Overall Status
Unknown status
CT.gov ID
NCT03527134
Collaborator
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (Other), Sun Yat-sen University (Other)
390
1
2
29.1
13.4

Study Details

Study Description

Brief Summary

Post-operative cognitive dysfunction (POCD) is a fairly well-documented clinical phenomenon. Investigators will determine whether amantadine can reduce the occurrence of POCD in elderly patients with major abdominal surgery.

Condition or Disease Intervention/Treatment Phase
N/A

Detailed Description

Patients who are 60 years old or older for laparoscopic abdominal surgery will be randomly assigned into two groups: 1) no-treatment group, and 2) amantadine-treated group. Each group will have 150 patients. In addition, investigators will need 90 subjects in the control group. The data of these control subjects will be used to normalize the data of the two studied groups to diagnose POCD. The subjects in control groups will also be elderly but without the exposure to anesthesia and surgery.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
390 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Two groups: one with amantadine treatment and the other with amantadine treatment.Two groups: one with amantadine treatment and the other with amantadine treatment.
Masking:
Triple (Participant, Care Provider, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Effects of Amantadine on Postoperative Cognitive Dysfunction in Elderly Patients With Elective Abdominal Surgery
Anticipated Study Start Date :
Apr 30, 2019
Anticipated Primary Completion Date :
Jul 1, 2021
Anticipated Study Completion Date :
Oct 1, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Amantadine treatment

To determine whether amantadine is effective in reducing the occurrence of postoperative cognitive dysfunction.

Drug: Amantadine
patients will receive amantadine 100 mg by month 2 h before the induction of general anesthesia and then 100 mg each time, three times per day for 5 days.

No Intervention: No-treatment

Patients will not receive any treatment.

Outcome Measures

Primary Outcome Measures

  1. Number of patients with postoperative cognitive dysfunction (POCD) (POCD is a composite outcome measure) [At 7 days after the surgery]

    The existence of POCD will be determined by Visual Verbal Learning Test based on the Rey's Auditory Recall of words, Concept Shifting Test, Stroop Color Word Interference Test and Letter-Digit Coding based on the Symbol Digit Substitution Test

Secondary Outcome Measures

  1. Number of patients with postoperative cognitive dysfunction (POCD) (POCD is a composite outcome measure) [At 3 months after the surgery]

    The existence of POCD will be determined by Visual Verbal Learning Test based on the Rey's Auditory Recall of words, Concept Shifting Test, Stroop Color Word Interference Test and Letter-Digit Coding based on the Symbol Digit Substitution Test

  2. Time for bowel function return after surgery [up to 2 weeks after the surgery]

  3. Degree of increase of stress hormone [Up to 5 days after the surgery]

    Adrenocorticotropic Hormone

  4. Length of hospital stay [Up to 3 months after the surgery]

  5. Degree of change in growth factor [Up to 5 days after the surgery]

    Brain-derived neurotrophic factor and glial cell derived neurotrophic factor

Eligibility Criteria

Criteria

Ages Eligible for Study:
60 Years to 100 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  1. major elective gynecological, prostate or bladder surgery patients who are ≥ 60 years old.

  2. the surgery is laparoscopic surgery and is expected to last for ≥ 2 hours under general anesthesia and the patient will stay in hospital for at least 7 days after surgery.

  3. lack of serious hearing and vision impairment and be able to read so that neurobehavioral tests can be performed.

Exclusion Criteria:
  1. Patients are not expected to be alive for longer than 3 months.

  2. Mini-mental State Examination (MMSE) [18] score ≤ 23.

  3. history of dementia, psychiatric illness or any diseases of central nervous system.

  4. current use of sedatives or antidepressant.

  5. alcoholism and drug dependence.

  6. patients previously included in this study (for patients who have second intra-abdominal surgery during the study period).

  7. difficult to follow up or patients with poor compliance.

  8. uncontrolled hypertension (> 180/100 mmHg)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Sun Yat-Sen Memorial Hospital Guangzhou Guangdong China 510120

Sponsors and Collaborators

  • Zhiyi Zuo
  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
  • Sun Yat-sen University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Zhiyi Zuo, Professor, Sun Yat-sen University
ClinicalTrials.gov Identifier:
NCT03527134
Other Study ID Numbers:
  • 2017-34
First Posted:
May 17, 2018
Last Update Posted:
Jan 3, 2019
Last Verified:
Jan 1, 2019
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 3, 2019